Skip to content

Positive Pressure Therapy to Optimize LUNG Function After Heart Surgery

Comparison Between Two Methods of Positive Pressure Therapy in the Prevention of Pulmonary Complications in the Immediate Postoperative Period of Cardiac Surgery: a Prospective, Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06611527
Acronym
PRO-LUNGHS
Enrollment
156
Registered
2024-09-25
Start date
2025-01-08
Completion date
2027-12-31
Last updated
2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Continuous Positive Airway Pressure, Heart Surgery, Physical Therapy Modalities, Postoperative Period, Pulmonary Atelectasis, Respiratory Function Tests

Brief summary

The most common cardiac surgeries are myocardial revascularization and valve replacement or plastic surgery. In the postoperative period of cardiac surgeries, the incidence of pulmonary complications ranges from 30% to 50% and is associated with increased length of hospital stay and morbidity and mortality. To reduce or minimize the occurrence of these complications, respiratory physiotherapy employs positive pressure reexpansion therapies, such as continuous positive airway pressure (CPAP) and positive pressure support with positive end-expiratory pressure (PS+PEEP). The goal of this clinical trial is to compare the effects of two positive pressure therapies, CPAP versus PS+PEEP, on the incidence of pulmonary complications in patients in the postoperative period of myocardial revascularization and valve replacement or plastic surgery, with mild to moderate pulmonary dysfunction. The main question it aims to answer is: Do patients in the immediate postoperative period of myocardial revascularization or valve replacement/plastic surgery, exhibiting mild to moderate pulmonary dysfunction, experience a comparable reversal of pulmonary conditions when treated with PS+PEEP versus CPAP? Participants will undergo the following assessments: spirometry, respiratory muscle strength testing, handgrip strength testing, and electrical impedance tomography. In the immediate postoperative period, participants will be randomized into two treatment groups: • Control Group PS+PEEP - application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%; • Experimental Group CPAP - application of CPAP at 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.

Interventions

DEVICEPS+PEEP group

Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%

Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.

Sponsors

InCor Heart Institute
CollaboratorOTHER
Federal University of São Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Immediate postoperative period of myocardial revascularization and/or valve replacement or plastic surgery; * Patients in the preoperative period at risk of developing pulmonary complications, characterized by the presence of at least 2 of the following risk factors: age ≥ 70 years, productive cough, diabetes, history of smoking, chronic obstructive pulmonary disease (COPD) defined by forced expiratory volume in 1 second (FEV1) lower than 75% of predicted, body mass index (BMI) ≥ 27 kg/m2, or only FEV1 lower than 80% and FEV1/forced vital capacity (FVC) ratio lower than 70% of predicted; OR patients in the postoperative period (up to 12 hours after extubation) with mild to moderate complications characterized by a pulmonary complication score lower than 3.

Exclusion criteria

* Hemodynamic instability characterized by mean arterial pressure (MAP) lower than 60mmHg and/or acute arrhythmia of any etiology; * Need for intra-aortic balloon; * Duration of invasive mechanical ventilation exceeding 24 hours after surgery; * Pulmonary complication score ≥ grade 3; * Presence of signs of acute respiratory failure, such as respiratory rate (f) ≥ 25 breaths/min and use of accessory muscles; * Chest tube with air leak; * Use of a pacemaker or implantable or external cardioverter-defibrillator.

Design outcomes

Primary

MeasureTime frameDescription
Severity of pulmonary complications in the postoperative periodParticipants will be followed for 7 days after surgery.Score of pulmonary complications adapted from previous publications, with 5 degrees, where the higher one (5) means death before hospital discharge, and degree 4 means need of invasive mechanical ventilation due to acute respiratory failure.
Electrical impedance tomography (EIT) ventilation distributionEIT ventilation distribution will be monitored during and 30 minutes after the therapies.

Secondary

MeasureTime frameDescription
Handgrip strengthAssessments will be conducted preoperatively, on the 5th and 7th postoperative days.
Maximal inspiratory and expiratory pressuresAssessments will be conducted preoperatively, on the 5th and 7th postoperative days.
Length of ICU stayFrom the day of surgery up to ICU discharge, an expected average of 2 days, and maximum censoring at day 28 after surgery.
Positive pressure therapy comfort levelThe level of comfort will be evaluated immediately after the first three positive pressure therapy sessions.Comfort during positive pressure therapy will be assessed using a visual analog scale ranging from 0 to 10, where 0 represents maximum comfort and 10 represents extreme discomfort.
Spirometry test resultsSpirometry will be conducted preoperatively, on the 5th and 7th postoperative days.Forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio from the spirometry test will be presented as percentages of predicted values.
Length of hospital stayFrom the day of surgery up to hospital discharge, an expected average of 10 days, and maximum censoring at day 28 after surgery.

Countries

Brazil

Contacts

Primary ContactMarcia S Volpe, PhD
marcia.volpe@unifesp.br+551133854255

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026